Lupin Share Price in Focus; Announces USFDA Approval and Launch of Sugammadex Injection

Lupin Limited has expanded its US injectable portfolio with the launch of Sugammadex Injection following approval from the United States Food and Drug Administration (US FDA), as per the exchange filings. 

The product has been introduced in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) strengths, both available as Single-Dose Vials.  

Sugammadex Injection Enters US Market 

Lupin's newly launched injection is bioequivalent to Bridion Injection from Merck, Sharp & Dohme LLC (Merck). 

The company received approval for its Abbreviated New Drug Application (ANDA) before commercially introducing the product in the United States.  

Product Used During Surgical Procedures 

Sugammadex Injection is used for the reversal of neuromuscular blockade caused by rocuronium bromide and vecuronium bromide. 

Its approved use covers adults and paediatric patients aged two years and above undergoing surgery.  

Lupin's Global Pharmaceutical Presence 

Headquartered in Mumbai, Lupin distributes its products across more than 100 markets. Its portfolio spans branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients. 

The company has established positions in India and the US across respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system and women's health therapies.  

Manufacturing and Research Network 

Lupin operates 15 manufacturing sites and seven research centres globally, supported by a workforce of more than 26,000 professionals. 

Its subsidiaries include Lupin Diagnostics, Lupin Digital Health and Lupin Manufacturing Solutions.  

Read More: L&T Share Price in Focus; Signs 6-Year EPC Framework Agreement with Petroleum Development Oman! 

Lupin Share Price Performance  

As of 31 July 2026, at 2:56 PM, Lupin Ltd share price was trading at ₹2,411.70 per share, reflecting a decline of 0.39% from the previous trading session. 

Conclusion 

The US launch adds Sugammadex Injection to Lupin's product portfolio in two single-dose vial strengths. The product is intended to reverse specific neuromuscular blockades in surgical patients aged two years and above.  

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.  

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.